BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

  Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, reported second quarter financial results for the period ending June 30, 2023 and provided business updates.

  August 11, 2023

   · 

  9 min read
• Drug Development

  Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

  Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) announced today the Phase 2 ELPIS II trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) and using the Company’s Lomecel-B™ asset in Hypoplastic Left Heart Syndrome (HLHS), has surpassed the 50% enrollment threshold.

  August 11, 2023

   · 

  6 min read